antiviral Archives -

US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid

Enanta lawsuit claims Pfizer’s Paxlovid infringes its patent

https://pharmaphorum.com/news/enanta-lawsuit-claims-pfizers-paxlovid-infringes-its-patent/

News/ News/ Patients

As cases rise, WHO says monkeypox risk is “moderate”

Phil Taylor antiviral, monkeypox, public health, Smallpox, vaccines, World Health Organisation 0 Comment

The World Health organisation’s latest assessment of the monkeypox outbreak is that it poses a moderate threat to

As cases rise, WHO says monkeypox risk is “moderate”

https://pharmaphorum.com/news/as-cases-rise-who-says-monkeypox-risk-is-moderate/

News/ News/ Patients

Monkeypox cases are rising. Should we be worried?

Phil Taylor antiviral, Bavarian Nordic, infectious disease, monkeypox, SIGA technologies, Smallpox, vaccine, World Health Organisation 0 Comment

The World Health Organization has said the current outbreak of monkeypox is the largest ever recorded outside sub-Saharan

Monkeypox cases are rising. Should we be worried?

https://pharmaphorum.com/news/monkeypox-cases-are-rising-should-we-be-worried/

News/ News/ Sales and Marketing

Merck makes $3.2bn from COVID-19 drug Lagevrio in Q1

Phil Taylor antiviral, coronavirus, COVID-19, Financial, Gardasil, Keytruda, Lagevrio, Merck & Co 0 Comment

Orders for Merck & Co’s oral antiviral for COVID-19 helped to swell the drugmaker’s first quarter revenues by

Merck makes $3.2bn from COVID-19 drug Lagevrio in Q1

https://pharmaphorum.com/news/merck-makes-3-2bn-from-covid-19-drug-lagevrio-in-q1/

News/ News/ R&D

Pfizer bulks up in RSV with $525m takeover of ReViral

Phil Taylor antiviral, infectious disease, M&A, paediatrics, Pfizer, respiratory syncytial virus, ReViral 0 Comment

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a

Pfizer bulks up in RSV with $525m takeover of ReViral

https://pharmaphorum.com/news/pfizer-bulks-up-in-rsv-with-525m-takeover-of-reviral/

News/ News/ R&D

Synairgen slumps as inhaled COVID drug fails pivotal test

Phil Taylor antiviral, coronavirus, COVID-19, interferon, respiratory, Synairgen 0 Comment

UK biotech Synairgen saw the value of its shares crater after its inhaled interferon beta therapy SNG001 was

Synairgen slumps as inhaled COVID drug fails pivotal test

https://pharmaphorum.com/news/synairgen-slumps-as-inhaled-covid-drug-fails-pivotal-test/

News/ News/ Sales and Marketing

FDA clears Gilead’s Veklury for COVID outpatients

Phil Taylor antiviral, coronavirus, COVID-19, fda, Gilead Sciences, NIH, Veklury 0 Comment

The FDA has extended the emergency use authorisation for Gilead Sciences’ antiviral Veklury to include non-hospitalised patients with

FDA clears Gilead’s Veklury for COVID outpatients

https://pharmaphorum.com/news/fda-clears-gileads-veklury-for-covid-outpatients/

News/ News/ R&D

After trial win, Novartis nabs COVID drug from Molecular Partners

Phil Taylor antiviral, coronavirus, COVID-19, DARPin, Molecular Partners, Novartis, partnering 0 Comment

There are still licensing deals to be done in the COVID-19 category it seems, after Novartis paid around

After trial win, Novartis nabs COVID drug from Molecular Partners

https://pharmaphorum.com/news/after-trial-win-novartis-nabs-covid-drug-from-molecular-partners/

Market Access/ News/ News

Update: Pfizer pips Merck to first oral COVID antiviral okay in US

Phil Taylor antiviral, coronavirus, COVID-19, fda, Merck & Co, molnupiravir, Paxlovid, Pfizer 0 Comment

Pfizer’s Paxlovid has become the first oral antiviral for COVID-19 to be authorised for emergency use by the

Update: Pfizer pips Merck to first oral COVID antiviral okay in US

https://pharmaphorum.com/news/pfizer-pips-merck-to-first-oral-covid-antiviral-okay-in-us/

Trending

antiviral

Login